Discussion

Advances in technology, in the particular area of native mass spectrometry, have enabled it to contribute to the drug discovery process within the pharmaceutical industry. This presentation will describe the use of native mass spectrometry to screen libraries of small molecules in order to assess their binding to biological targets. In particular the development of a fully automated screen capable of detecting fragment binding in the millimolar KD range will be discussed. The use of hydrogen deuterium exchange mass spectrometry to elucidate binding epitopes and conformational change will also be described.